CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
Kamada says it can meet rising U.S. demand for KedRAB as CDC data show higher rabies exposures and greater PEP immunoglobulin use.
Rhea-AI Summary
Kamada (KMDA) reports that current inventory and manufacturing capacity are sufficient to meet increased U.S. demand for KedRAB, following a CDC Health Advisory on a year-over-year rise in nationwide human rabies exposures and use of post-exposure prophylaxis (PEP).
KedRAB, supplied in the United States via Kedrion Biopharma, is a human rabies immune globulin and one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. Kamada estimates the U.S. rabies immunoglobulin market at approximately $200 million annually. The company highlights its vertically integrated supply chain, long-standing Kedrion partnership, and recent FDA approval of its in-house rabies testing lab as support for reliable, uninterrupted KedRAB supply.
Positive
- KedRAB supply and capacity confirmed sufficient to meet increased U.S. demand
- KedRAB is one of only two FDA-approved anti-rabies immunoglobulin products for PEP in the U.S.
- Kamada estimates the U.S. rabies immunoglobulin market at approximately $200 million annually
- Recent FDA approval of Kamada’s in-house rabies testing lab supports ongoing KedRAB supply
Negative
- None.
Key Figures
- Annual U.S. rabies exposure care
- 1.4 million people
- CDC estimate per year
- Annual U.S. PEP treatment
- 100,000 people
- CDC estimate per year
- U.S. rabies immunoglobulin market
- $200 million annually
- Kamada estimate
- FDA-approved anti-rabies immunoglobulin products
- 2 products
- U.S. market; KedRAB is one of two
Key Terms
post-exposure prophylaxis medical
human rabies immune globulin medical
hrig medical
anaphylaxis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization
- KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at
$200 Million Annually - Kamada’s Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (the “Company”), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today confirmed that it maintains sufficient KedRAB® supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory published by the U.S. Centers for Disease Control and Prevention (CDC) on September 10, 2026, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis (PEP). The CDC Health Advisory is available at:
https://www.cdc.gov/han/php/notices/han00533.html.
In light of this increase in end-user utilization described in the CDC advisory, Kamada confirms it has the inventory and manufacturing capacity to support the continued supply of KedRAB, a human rabies immune globulin developed and manufactured by Kamada, which is one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. The product is supplied to the U.S. market via the Company’s U.S. commercialization partner, Kedrion Biopharma Inc.
“Kamada is a global leader in human rabies prevention using immunoglobulin and we remain committed to delivering reliable, uninterrupted supply of KedRAB to meet the needs of patients and clinicians across the United States,” said Amir London, Chief Executive Officer of Kamada. “Our long-standing successful partnership with Kedrion, together with our vertically integrated supply chain, and the recent FDA approval of our in-house rabies testing lab, position us to respond to this year-over-year increase in demand while maintaining the consistency and quality that this lifesaving therapeutic requires.”
Rabies is a deadly viral disease that attacks the brain and nervous system of mammals, including humans. The CDC estimates that approximately 1.4 million people in the United States seek medical care for a possible rabies exposure each year, of whom approximately 100,000 receive PEP treatment. Kamada estimates the total U.S. market for rabies immunoglobulin products at approximately
INDICATION AND SELECTED IMPORTANT SAFETY INFORMATION
INDICATION: KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.
IMPORTANT SAFETY INFORMATION ABOUT KedRAB: Severe hypersensitivity reactions, including anaphylaxis, may occur with KedRAB. IgA deficient patients with antibodies against IgA are at greater risk. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions. KedRAB administration may interfere with the development of an immune response to live attenuated virus vaccines. If feasible, delay immunization with the measles vaccine for 4 months, and other live attenuated virus vaccines for three months, after KedRAB administration. A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests after KedRAB administration. Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs’ test). KedRAB is made from human plasma donors and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-353-7466 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. I.D. Code: KAM.001-26
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: (1) the sufficiency of the Company's KedRAB inventory and manufacturing capacity to meet current and future U.S. demand; and (2) expectations regarding continued or increased demand for KedRAB in the United States. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including, but not limited to: the unpredictable and seasonal nature of rabies exposure trends and the possibility that reported increases in demand do not continue or recur; Kamada's reliance on Kedrion as its sole distributor of KedRAB in the United States and any change in that relationship; Kamada's ability to manufacture sufficient quantities of KedRAB and to obtain adequate quantities of hyper-immune plasma and other raw materials on a timely basis; competition from other rabies immunoglobulin and rabies biologic products; the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world; the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally; the effect of tariffs on overall international trade and specifically on Kamada's ability to maintain expected sales and profit levels in light of such tariffs; the effect on the establishment and timing of business initiatives; Kamada’s ability to leverage new business opportunities and integrate them with its existing product portfolio; unexpected results of clinical and development programs; regulatory delays; and other risks detailed in Kamada's filings with the U.S. Securities and Exchange Commission (the “SEC”), including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file with, or furnished to, the SEC and available on the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the CDC report that is driving increased demand for KedRAB?
The CDC issued a Health Advisory on September 10, 2026, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis (PEP). Kamada links its confirmation of KedRAB supply availability to this increase in end-user utilization described in the advisory.
What is KedRAB indicated for?
KedRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis of rabies infection in persons of all ages when given immediately after contact with a rabid or possibly rabid animal. It should be administered concurrently with a full course of rabies vaccine.
What key safety information is highlighted for KedRAB?
Severe hypersensitivity reactions, including anaphylaxis, may occur, especially in IgA-deficient patients with antibodies against IgA, so epinephrine should be available. KedRAB may interfere with immune responses to live attenuated virus vaccines, so measles vaccine is advised to be delayed 4 months and other live attenuated vaccines 3 months after administration if feasible. Passive antibodies may cause misleading positive serologic test results and may interfere with red cell antibody tests such as the Coombs’ test. As a plasma-derived product, KedRAB may carry a risk of transmitting infectious agents such as viruses and variant Creutzfeldt-Jakob disease (vCJD) agents.
How large is the rabies exposure and PEP-treated population in the U.S.?
The CDC estimates that approximately 1.4 million people in the United States seek medical care each year for a possible rabies exposure, and approximately 100,000 of them receive rabies post-exposure prophylaxis (PEP) treatment.
How is KedRAB supplied in the U.S. market?
KedRAB is developed and manufactured by Kamada and supplied to the U.S. market through Kamada’s U.S. commercialization partner, Kedrion Biopharma.